세계 손바닥 섬유종증 시장 – 2024-2031

Report Overview
The Global Palmar Fibromatosis Market reached US$ 4.17 billion in 2023 and is expected to reach US$ 6.05 billion by 2031, growing at a CAGR of 4.8% during the forecast period 2024-2031.
Palmar fibromatosis is a hereditary condition that transforms the fibrous tissue in the palm into cords and nodules. It is a progressive disease that can cause severe contracture to fingers and thumb and heavily compromises hand function. The condition starts with the thickening of tissue in the palm in line with a finger. In most cases a nodule forms at the base of the ring finger first. As the fibromatosis progresses a cord forms that crosses the first finger joint (metacarpophalangeal joint /MCPJ). This is when a visible contracture appears.
The palmar fibromatosis is also known as dupuytren's contracture. The palmar fibromatosis is a benign(non-cancerous) condition. Radiotherapy can be used to treat palmar fibromatosis. Radiotherapy stops, or slows down, the progression of the condition, and reduces the size of the lumps in the hand.
Market Dynamics: Drivers
Increasing prevalence of palmar fibromatosis
The demand for the global palmar fibromatosis market is driven by multiple factors. The rising prevalence of palmar fibromatosis propels the market growth.
Furthermore, the demand for treatment will be fueled by the increase in technological advancements. For instance, according to nih.gov, Palmar fibromatosis is the most common type of superficial fibromatosis affecting approximately 1%–2% of the population. The prevalence increases with the patient’s age to where approximately 20% of the population at age 65 suffers from this disease. Males are more often affected, with a male-to-female ratio of 3–4:1. It can affect both the metacarpophalangeal and proximal interphalangeal joints. Half of the cases affect both hands. Patients of northern European ancestry are most commonly affected and the disease is rare in the black population.
The disease process usually affects the medial and central bands of the plantar aponeurosis of middle-aged patients. Approximately 25% of cases are bilateral with males being more affected than females. A possible genetic predisposition has been suggested, as two genetic variants were found in a genome-wide association study where one indel (chr5:118704153:D) and one single nucleotide polymorphism (rs62051384) were detected.
Restraints
Factors such as the high cost associated with the treatment, lack of awareness among people, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.
Market Segment Analysis
The global palmar fibromatosis market is segmented based on treatment, end-user, and region.
The segment injections accounted for approximately 47.2% of the global palmar fibromatosis market share
The injections segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for clinical trials would drive this market.
The collagenase and steroid injections are widely used for the treatment of palmar fibromatosis. For instance, according to nih.gov, The FDA and EMA approved the use of collagenase to treat palmar fibromatosis (Dupuytren’s contracture). The approved treatment includes up to three (in palmar fibromatosis) or up to eight (in penile fibromatosis) injections followed by finger extension or penile modeling procedures, typically causing severe pain.
Collagenases are enzymes that break down collagen, and a targeted collagenase was created to specifically break down the collagen in Dupuytren's cords without damaging the collagen of the other important structures of the hand. When injected properly into a Dupuytren's cord, this collagenase can help rupture the cord, allowing for improved motion of the digit (finger or thumb). While the collagenase does not completely remove the cord, symptoms can still be improved following treatment.
Market Geographical Share
Europe accounted for approximately 30.6% of the global palmar fibromatosis market share
The rising incidence of palmar fibromatosis, in this region, helps to propel the market. For instance, according to nih.gov, palmar fibromatosis (Dupuytren disease) is the most common of the superficial fibromatosis, affecting 1%-2% of the general population. Palmar fibromatosis is rare in Asian and African populations but frequent in the Northern European countries of Norway, Iceland, and Scotland, with prevalence rates between 30% and 39%. The etiology of palmar fibromatosis is believed to be multifactorial, including components of trauma, microvascular injury, immunologic processes, and genetic factors.
The ratio of men to women affected with palmar fibromatosis is 7:1 in Europe. In Europe, orthovoltage radiation therapy (RT) has been demonstrated to prevent local disease progression for up to 80% of patients with early-stage palmar fibromatosis. En face electron, RT is an effective therapy that stabilizes or improves symptoms in the majority of patients. Reirradiation can be considered as a treatment option for in-field progression. Patients report minimal toxicity and a high rate of satisfaction with treatment.
Market Segmentation
By Treatment
• Needling
• Injections
• Steroids
• Collagenase
• Surgery
• Hand Therapy
• Others
By End-User
• Hospitals
• Specialty Clinics
• Others
By Region
• North America
o The U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Market Competitive Landscape
The major global players in the palmar fibromatosis market include Pfizer Inc., Novartis AG, Bayer AG, GSK plc., AstraZeneca, Leo Pharma, Hikma Pharmaceuticals plc., Nantong Jinghua Pharmaceuticals Co. Ltd., Bristol Meyers Squibb Company, Endo Inc. among others.

Key Developments
• In May 2023, Ventoux Biosciences officially launched its efforts to deliver life-changing therapies for patients with Dupuytren’s disease, a common, progressive, debilitating fibrotic contracture that limits hand mobility. An injection called collagenase clostridium histolyticum (XIAFLEX®) is approved by the FDA when a palpable cord and contracture are present, meaning that the disease is already in its late stage.
• In March 2023, Endo International announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fibromatosis. While the primary endpoint when analyzed with the overall study population did not meet statistical significance, a large patient sub-population showed statistically significant improvement. The primary endpoint was an improvement from baseline in the Foot Function Index (FFI) Pain Scale score when compared to those receiving a placebo.
Why Purchase the Report?
• To visualize the global palmar fibromatosis market segmentation based on treatment, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global palmar fibromatosis market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global palmar fibromatosis market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies